What is RYTELO?

RYTELO (imetelstat) is a prescription medicine used to treat a condition called low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults: See more

  • with anemia (low red blood cell counts) who need blood transfusions of 4 or more red blood cell units over 8 weeks

and

  • who have not responded to, have stopped responding to, or cannot be treated with medicines called erythropoiesis-stimulating agents (ESAs).

It is not known if RYTELO is safe and effective in children.

Resources for patients and care teams

Downloadable resources designed to provide the best possible experience with RYTELO.

Downloadable resources designed to provide the best possible experience with RYTELO.

RYTELO Patient Brochure

Use this brochure to discuss the potential benefits and risks of treatment and how they may be managed.

Open Brochure
Share
A woman with a puffer vest smiles.

  • REACH4RYTELO® Patient Enrollment Form

    The REACH4RYTELO Patient Support Program helps patients understand insurance coverage and access treatment. To enroll, this form must be completed by both the patient and their care team.

    Open Form

    Share

  • REACH4RYTELO® Copay Program Brochure

    The Copay Program may provide financial support to eligible patients with commercial insurance. This brochure can help you learn more about the support that may be available.

    Open Brochure

    Share

REACH4RYTELO patient support program logo
Learn more about the support available to patients prescribed RYTELO icon-crosslink_arrow-v2
A woman smiling with her arms crossed

Additional resources for patients and caregivers

The organizations listed below provide trusted education about myelodysplastic syndromes (MDS), including information on diagnosis, treatment options, and ongoing care. They also offer a wide range of resources, support services, and guidance for people living with MDS and for their families and caregivers. They have not endorsed Geron Corporation or any of its respective products or services.

These organizations are independent groups and are shared here for informational purposes only. Inclusion does not imply endorsement of any organization or its content.

AA-MDS (Aplastic Anemia & MDS International Foundation) logo
AA-MDS (Aplastic Anemia & MDS International Foundation) logo
MDS Foundation logo
MDS Foundation logo
Blood Cancer United logo
Blood Cancer United logo
HealthTree Foundation logo
HealthTree Foundation logo
Cancer Support Community logo
Cancer Support Community logo
CancerCare logo
CancerCare logo
American Cancer Society logo
American Cancer Society logo
The Patient Story
The Patient Story
Triage Cancer Logo
Triage Cancer Logo
NCCN Foundation Patient Resources Logo
NCCN Foundation Patient Resources Logo
Patient Empowerment Network
Patient Empowerment Network

  • For the care team

    See the clinical practice guidelines and access additional RYTELO resources to use with your patients.

Visit the RYTELO HCP website icon-crosslink_button_gold-v2

  • Your story can make a difference

    Share your RYTELO experience to help others living with lower-risk MDS with anemia.

See how to participate icon-crosslink_button_gold-v2
Expand

What is RYTELO?

RYTELO (imetelstat) is a prescription medicine used to treat a condition called low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults:

  • with anemia (low red blood cell counts) who need blood transfusions of 4 or more red blood cell units over 8 weeks

and

  • who have not responded to, have stopped responding to, or cannot be treated with medicines called erythropoiesis-stimulating agents (ESAs).

It is not known if RYTELO is safe and effective in children.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide.

Important Safety Information

Before you receive RYTELO, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. RYTELO may harm your unborn baby and may cause loss of pregnancy (miscarriage). Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with RYTELO.

Females who are able to become pregnant:

  • Your healthcare provider will perform a pregnancy test before you are given RYTELO.
  • You should use effective birth control (contraception) during treatment with RYTELO and for 1 week after your last dose.
  • are breastfeeding or plan to breastfeed. It is not known if RYTELO passes into your breastmilk. Do not breastfeed during treatment with RYTELO and for 1 week after your last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What is the most important information I should know about RYTELO?

RYTELO may cause serious side effects, including:

  • Low platelet counts (thrombocytopenia). Low platelet counts are common during treatment with RYTELO and can also be severe. Low platelet counts can increase your risk for bleeding. Your healthcare provider may give you platelet transfusions to reduce the risk of bleeding if you develop a low platelet count during treatment with RYTELO. Tell your healthcare provider right away if you develop any signs or symptoms of bleeding, including:
    • unusual bleeding or bruising
    • bleeding that lasts a long time
    • nosebleeds
    • vomiting blood
    • blood in your stool or black tarry stool
  • Low neutrophil counts (neutropenia). Low counts of a type of white blood cell called neutrophils are common during treatment with RYTELO and can also be severe. Low neutrophil counts can increase your risk for infections, including serious infections and sepsis. Your healthcare provider may give you medicines before you start treatment to help prevent neutropenia and infections and may treat you with medicines if you develop these problems during treatment with RYTELO. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with RYTELO, including:
    • fever
    • shortness of breath or trouble breathing
    • cough
    • chills
    • pain or burning when you urinate

Your healthcare provider will do blood tests to check your platelet and neutrophil counts before starting treatment with RYTELO, weekly for the first 2 cycles of treatment, before you receive each additional cycle, and as needed during your treatment.

Your healthcare provider may delay your next treatment, decrease your dose, or stop treatment with RYTELO if you develop thrombocytopenia or neutropenia during treatment.

What are the possible side effects of RYTELO?

RYTELO may cause serious side effects, including:

  • See “What is the most important information I should know about RYTELO?”
  • Infusion-related reactions. RYTELO can cause infusion-related reactions during or after your infusion that can be severe, including a severe sudden increase in blood pressure called hypertensive crisis. Your healthcare provider will give you medicines before each RYTELO infusion to help prevent or lessen infusion-related reactions and will watch you for at least 1 hour after your infusion. If you develop infusion-related reactions, your healthcare provider may infuse RYTELO more slowly, temporarily stop, or permanently stop your treatment. Tell your healthcare provider if you develop any signs or symptoms of infusion-related reactions, including:
    • stomach pain
    • joint pain
    • weakness and tiredness
    • back and bone pain
    • diarrhea
    • redness
    • headache
    • high blood pressure
    • not feeling well
    • chest pain that is not related to your heart
    • itching
    • hives

The most common side effects of RYTELO include:

  • decreased platelet counts
  • decreased white blood cell counts
  • decreased neutrophil counts
  • increased liver enzymes (AST, alkaline phosphatase, and ALT)
  • tiredness
  • longer than usual blood clotting times
  • joint, bone and muscle pain
  • Covid-19 infections
  • headache

These are not all of the possible side effects of RYTELO. Call your doctor for more information and medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide.

What is RYTELO?

RYTELO (imetelstat) is a prescription medicine used to treat a condition called low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults:

  • with anemia (low red blood cell counts) who need blood transfusions of 4 or more red blood cell units over 8 weeks

and

  • who have not responded to, have stopped responding to, or cannot be treated with medicines called erythropoiesis-stimulating agents (ESAs).

It is not known if RYTELO is safe and effective in children.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide.

Important Safety Information

Before you receive RYTELO, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. RYTELO may harm your unborn baby and may cause loss of pregnancy (miscarriage). Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with RYTELO.

Females who are able to become pregnant:

  • Your healthcare provider will perform a pregnancy test before you are given RYTELO.
  • You should use effective birth control (contraception) during treatment with RYTELO and for 1 week after your last dose.
  • are breastfeeding or plan to breastfeed. It is not known if RYTELO passes into your breastmilk. Do not breastfeed during treatment with RYTELO and for 1 week after your last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What is the most important information I should know about RYTELO?

RYTELO may cause serious side effects, including:

  • Low platelet counts (thrombocytopenia). Low platelet counts are common during treatment with RYTELO and can also be severe. Low platelet counts can increase your risk for bleeding. Your healthcare provider may give you platelet transfusions to reduce the risk of bleeding if you develop a low platelet count during treatment with RYTELO. Tell your healthcare provider right away if you develop any signs or symptoms of bleeding, including:
    • unusual bleeding or bruising
    • bleeding that lasts a long time
    • nosebleeds
    • vomiting blood
    • blood in your stool or black tarry stool
  • Low neutrophil counts (neutropenia). Low counts of a type of white blood cell called neutrophils are common during treatment with RYTELO and can also be severe. Low neutrophil counts can increase your risk for infections, including serious infections and sepsis. Your healthcare provider may give you medicines before you start treatment to help prevent neutropenia and infections and may treat you with medicines if you develop these problems during treatment with RYTELO. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with RYTELO, including:
    • fever
    • shortness of breath or trouble breathing
    • cough
    • chills
    • pain or burning when you urinate

Your healthcare provider will do blood tests to check your platelet and neutrophil counts before starting treatment with RYTELO, weekly for the first 2 cycles of treatment, before you receive each additional cycle, and as needed during your treatment.

Your healthcare provider may delay your next treatment, decrease your dose, or stop treatment with RYTELO if you develop thrombocytopenia or neutropenia during treatment.

What are the possible side effects of RYTELO?

RYTELO may cause serious side effects, including:

  • See “What is the most important information I should know about RYTELO?”
  • Infusion-related reactions. RYTELO can cause infusion-related reactions during or after your infusion that can be severe, including a severe sudden increase in blood pressure called hypertensive crisis. Your healthcare provider will give you medicines before each RYTELO infusion to help prevent or lessen infusion-related reactions and will watch you for at least 1 hour after your infusion. If you develop infusion-related reactions, your healthcare provider may infuse RYTELO more slowly, temporarily stop, or permanently stop your treatment. Tell your healthcare provider if you develop any signs or symptoms of infusion-related reactions, including:
    • stomach pain
    • joint pain
    • weakness and tiredness
    • back and bone pain
    • diarrhea
    • redness
    • headache
    • high blood pressure
    • not feeling well
    • chest pain that is not related to your heart
    • itching
    • hives

The most common side effects of RYTELO include:

  • decreased platelet counts
  • decreased white blood cell counts
  • decreased neutrophil counts
  • increased liver enzymes (AST, alkaline phosphatase, and ALT)
  • tiredness
  • longer than usual blood clotting times
  • joint, bone and muscle pain
  • Covid-19 infections
  • headache

These are not all of the possible side effects of RYTELO. Call your doctor for more information and medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide.

C-US-RYT-IM-0343 05/2026 © 2026 Geron Corp. All rights reserved. GERON, GERON logo, RYTELO, RYTELO logo, and REACH4RYTELO are registered trademarks of Geron Corporation.

This link will take you to a website that is outside the control of Geron. Links are provided as a courtesy for informational purposes only. We do not make or imply any endorsement of external websites.

Continue

No, stay on RYTELO.com

The site you are about to enter is intended for US healthcare professionals.
Please confirm that you are a US healthcare professional.

Return
Yes, I am a US healthcare professional

Thank you!

Your information has been submitted.
We will be in touch soon!